FIELD: medicine.
SUBSTANCE: invention refers to pro-drug preparations consisting of peptides of the glucagon superfamily, wherein the above peptide of the glucagon superfamily has been modified by dipeptide attaching to the peptide of the glucagon superfamily by an amide bond.
EFFECT: pro-drugs described above have a long half-life and are able to transform into an active form in the physiological environment by means of a non-enzymatic reaction induced by chemical instability.
16 cl, 18 dwg, 19 tbl, 19 ex
| Title | Year | Author | Number |
|---|---|---|---|
| AMIDE-BASED PRODRUGS OF GLUCAGON SUPERFAMILY PEPTIDES | 2009 |
|
RU2550696C2 |
| GLUCAGON SUPERFAMILY PEPTIDES EXHIBITING NUCLEAR HORMONE RECEPTOR ACTIVITY | 2011 |
|
RU2604067C2 |
| INSULIN-INCRETIN CONJUGATES | 2014 |
|
RU2678134C2 |
| PRODRUGS CONTAINING HYALURONIC ACID CONJUGATE, LINKER AND DOUBLE AGONIST GLP-1/GLUCAGON | 2016 |
|
RU2719482C2 |
| DIPEPTIDE LINKED MEDICINAL AGENTS | 2009 |
|
RU2578591C2 |
| POLYPEPTIDES SELECTIVE TO GLUCAGON RECEPTORS AND THEIR APPLICATION METHODS | 2017 |
|
RU2760007C2 |
| GLUCAGON ANALOGUES, POSSESSING HIGHER SOLUBILITY AND STABILITY IN BUFFERS WITH PHYSIOLOGICAL Ph VALUES | 2009 |
|
RU2560254C2 |
| PEPTIDE DRUGS WITH HIGH EFFECTIVENESS AGAINST INSULIN RESISTANCE | 2012 |
|
RU2602801C2 |
| DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS | 2013 |
|
RU2652783C2 |
| ARYL, HETEROARYL AND HETEROCYCLIC PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS | 2018 |
|
RU2801278C2 |
